Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc.

VTYX·NASDAQ

$14.00

+0.0000%
HealthcareBiotechnology

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

At a Glance

Live Snapshot
Market Cap$1.00B
EPS-1.9700
P/E Ratio-7.11
Earnings Date03/05/2026

No Dividend Yield Data

VTYX has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

VTYX has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

VTYX has not reported any net dividends paid values in the available annual periods.

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. Dividend History

VTYX · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

VTYX Dividend Payment History

VTYX · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
vtyx

Ventyx Biosciences, Inc. Payout Ratio Analysis

VTYX · NASDAQ
Dividends Paid
0.00
2024
Net Income
-135.12M
2024
Payout Ratio
0.00%
2024

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.